ID   LUCC7
AC   CVCL_W898
DR   cancercelllines; CVCL_W898
DR   Cosmic; 2050455
DR   Cosmic; 2686107
DR   Wikidata; Q54903253
RX   PubMed=24035680;
RX   PubMed=24367658;
RX   PubMed=29732388;
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.-57A>C (c.161A>C) (A161C); ClinVar=VCV000242210; Zygosity=Unspecified; Note=In promoter (PubMed=24035680).
CC   Derived from site: In situ; Kidney, renal pelvis; UBERON=UBERON_0001224.
DI   NCIt; C6142; Renal pelvis carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_A8Y0 ! LUCC7EBV
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 17-07-14; Last updated: 05-10-23; Version: 10
//
RX   PubMed=24035680; DOI=10.1016/j.eururo.2013.08.057;
RA   Hurst C.D., Platt F.M., Knowles M.A.;
RT   "Comprehensive mutation analysis of the TERT promoter in bladder
RT   cancer and detection of mutations in voided urine.";
RL   Eur. Urol. 65:367-369(2014).
//
RX   PubMed=24367658; DOI=10.1371/journal.pone.0084411;
RA   Ross R.L., Burns J.E., Taylor C.F., Mellor P., Anderson D.H.,
RA   Knowles M.A.;
RT   "Identification of mutations in distinct regions of p85 alpha in
RT   urothelial cancer.";
RL   PLoS ONE 8:E84411-E84411(2013).
//
RX   PubMed=29732388; DOI=10.3233/BLC-180167;
RA   Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.;
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).
//